EZH2 and colorectal cancer: GSK126 increases the number of myeloid-derived suppressor cells (MDSCs) and decreases CD4+ and IFNΥ CD8+ T-cells, which is associated with antitumor immunity in colorectal cancer, via EZH2-mediated H3k27me3 levels (Huang et al., 2019).